文献速递其他结缔组织病

自体造血干细胞移植前后系统性硬化症患者健康相关生活质量:系统综述

Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该系统综述纳入8项研究(含3项非盲随机对照试验),共289例接受自体造血干细胞移植(AHSCT)和125例接受静脉环磷酰胺(CYC)对照的系统性硬化症(SSc)患者,随访中位1.25-4.5年。AHSCT与HAQ-DI、SF-36生理成分总结评分及EQ-5D效用评分的显著改善相关,但SF-36心理成分总结评分改善不一致。

要点

  • AHSCT与SSc患者HAQ-DI、SF-36生理成分及EQ-5D评分的显著改善相关。
  • SF-36心理成分总结评分仅在ASSIST试验和小型回顾队列中改善,两项RCT未显著改善。
  • 纳入研究质量为中至低,证据强度有限。

核心结论

  • 在严重SSc患者中,AHSCT与生理健康相关生活质量的显著且持久改善相关。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索PubMed和ScienceDirect从建库至2019年2月1日,纳入8篇文章(3项非盲RCT、3项非对照I/II期试验、2项队列研究)。
  • 共纳入289例接受AHSCT和125例接受静脉CYC对照的SSc患者,随访中位1.25-4.5年。

主要发现

  • AHSCT与HAQ-DI显著改善相关(P=0.02-<0.001)。
  • AHSCT与SF-36生理成分总结评分显著改善相关(P=0.02-<0.0001)。
  • AHSCT与EQ-5D指数效用评分显著改善相关(P<0.001)。
  • SF-36心理成分总结评分在ASSIST(n=19)和一项小型回顾队列(n=30,P=0.005)中改善,但在两项RCT(n=200,P=0.1-0.91)中未显著改善。

关键数值与推荐

  • HRQoL评估工具包括HAQ-DI(275例)、SF-36(249例)和EQ-5D(138例)。
  • 纳入研究质量评估为中至低。

临床怎么用

  • 对于严重SSc患者,AHSCT可考虑用于改善生理健康相关生活质量。
  • 心理生活质量改善证据不一致,需个体化评估。

局限性

  • 纳入研究质量为中至低。
  • 部分分析基于非盲随机对照试验和非对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In severe rapidly progressive SSc, autologous haematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event-free survival. We undertook this study to identify, appraise and synthesize the evidence on health-related quality of life (HRQoL) before and after AHSCT for SSc. METHODS: We performed a systematic review of the literature, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, in PubMed and ScienceDirect from database inception to 1 February 2019. All articles with original HRQoL data were selected. RESULTS: The search identified 1080 articles, of which 8 were selected: 3 unblinded randomized controlled trials [American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST), Autologous Stem Cell Transplantation International Scleroderma, Scleroderma: Cyclophosphamide or Transplantation), 3 uncontrolled phase I or II trials and 2 cohort studies. HRQoL data from 289 SSc patients treated with AHSCT and 125 treated with intravenous CYC as a comparator with median 1.25-4.5 years follow-up were included. HRQoL was evaluated with the HAQ Disability Index (HAQ-DI; 275 patients), the 36-item Short Form Health Survey (SF-36; 249 patients) and the European Quality of Life 5-Dimensions questionnaire (EQ-5D; 138 patients). The quality of the studies was moderate to low. AHSCT was associated with significant improvement in the HAQ-DI (P = 0.02-<0.001), SF-36 Physical Component Summary score (P = 0.02-<0.0001) and EQ-5D index-based utility score (P < 0.001). The SF-36 Mental Component Summary score improved in the ASSIST (n = 19) and one small retrospective cohort (n = 30 patients, P = 0.005) but did not improve significantly in 2 randomized controlled trials (n = 200 patients, P = 0.1-0.91). CONCLUSION: AHSCT in severe SSc patients is associated with significant and durable improvement in physical HRQoL.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Puyade M, Maltez N, Lansiaux P, et al. Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review. Rheumatology (Oxford). 2020. PMID: 31504944. doi:10.1093/rheumatology/kez300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。